High prevalence of parvovirus B19 IgG antibodies among Dutch hemophilia patients

Vox Sang. 1998;74(4):225-7.


Background and objectives: Human parvovirus B19 is a potential risk to hemophiliac patients receiving blood products.

Materials and methods: To determine the prevalence of the corresponding antibody in patients with hemophilia A or B von Willebrand's disease, we tested 326 hemophilia patients for anti-B19 IgG. The results were compared with those of 203 age-matched controls (male blood donors and children).

Results: The overall prevalence of B19 IgG in the hemophilia patients was 302/326, and in the controls 123/203. Below the age of 10, hemophilia patients had a higher prevalence of B19 IgG (76%, 42/55) than the controls (23%, 11/48; p < 0.00001). In those below the age of 5 who had been treated exclusively with monoclonally purified concentrate, it made no difference whether the product was pasteurized or solvent-detergent treated. There was significantly lower incidence in patients who were rarely treated.

Conclusion: Parvovirus B19 if frequently transmitted in blood products. Existing virus-inactivating methods do not prevent transmission.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Antibodies, Viral / blood
  • Blood Coagulation Factors / adverse effects
  • Blood Coagulation Factors / therapeutic use
  • Child
  • Child, Preschool
  • Hemophilia A / blood
  • Hemophilia A / epidemiology*
  • Humans
  • Immunoglobulin G / blood
  • Infant
  • Male
  • Middle Aged
  • Netherlands / epidemiology
  • Parvoviridae Infections / epidemiology*
  • Parvoviridae Infections / immunology*
  • Parvoviridae Infections / transmission
  • Parvovirus B19, Human / immunology*
  • Prevalence
  • Risk Factors
  • von Willebrand Diseases / epidemiology


  • Antibodies, Viral
  • Blood Coagulation Factors
  • Immunoglobulin G